Market Overview

UPDATE: McNicoll Lewis Vlak Initiates Galena Biopharma at Buy on Cancer Vaccine Potential

Share:
Related GALE
15 Stocks Moving In Tuesday's Pre-Market Session
Mid-Afternoon Market Update: Dow Surges 250 Points; Juno Therapeutics Shares Tumble

McNicoll Lewis Vlak initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $6 price target.

McNicoll Lewis Vlak commented, "As we near the end of Breast Cancer Awareness month, we are initiating coverage on Galena Biopharma Inc. with a BUY recommendation and one-year price target of $6.00 based on the company's lead Phase III asset, a cancer vaccine called NeuVax. An ongoing Phase III trial, being conducted under a Special Protocol Assessment (SPA), is targeting breast cancer patients who are classified as HER2/neu negative but have node-positive disease. Breast cancer affects one in eight women, and we believe NeuVax will be able to prolong the lives of those who are fortunate enough to catch their disease early."

Galena Biopharma closed at $1.88 on Wednesday.

Latest Ratings for GALE

DateFirmActionFromTo
Jun 2016Raymond JamesDowngradesOutperformMarket Perform
Mar 2016Roth CapitalMaintainsBuy
Dec 2015Cantor FitzgeraldUpgradesSellHold

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: mcnicoll lewis vlakAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

View Comments and Join the Discussion!